Form 4: Lyell Immunopharma Director Receives Stock Option Grant

Director Mark Bachleda was granted 9,250 stock options in Lyell Immunopharma, Inc. as part of standard equity compensation.

Summary

• Director Mark Bachleda received a grant of 9,250 stock options on June 10, 2026.
• The options have an exercise price of $13.22 per share.
• The options are set to expire on June 9, 2036.
• Vesting occurs on the earlier of the next annual stockholder meeting or the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• The grant represents potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Lyell Immunopharma stock exceeding the $13.22 strike price.

Future Outlook

The options vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, contingent upon continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent, though they remain subject to market volatility.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Lyell Immunopharma, LYEL, Form 4, Insider Trading, Stock Options, Director Compensation